Clinical trials: Soft-tissue Sarcomas
Sarcoma
Establishment of a Prospective Clinical-biological Database
A Clinical and Biological Database will provide to the scientific community a collection of blood and tissues with clinical data to improve knowledge about cancer and help to develope new cancer treatments.
- Trial name
- BCBSarcome (NCT04458792)
- Testing
- Paraffin tissue samples, blood sample
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Liposarcoma, Osteogenic Sarcoma
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
Although regorafenib was approved for use in patients who had progressive GIST despite imatinib and/or sunitinib on the basis of phase II and phase III data, it has not been examined in a systematic fashion in patients with other…
- Conditions
- Liposarcoma, Osteogenic Sarcoma, Ewing/Ewing-like Sarcoma, Rhabdomyosarcoma
- Trial name
- NCT02048371
- Testing
- Regorafenib
- Where
- 18 sites in United States
- Volunteers
- 131 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Soft Tissue Sarcoma
Application of Contrast-enhanced Ultrasound in Monitoring Soft Tissue Sarcoma Response to Neoadjuvant Radiotherapy
This pilot study will evaluate the feasibility of applying CEUS as imaging guidance for planning RT and predicting RT response. The investigators will determine if US-CT/MRI fusion is feasible and if tumor vascularity and…
- Trial name
- NCT07436364
- Testing
- Definity, Contrast-Enhanced Ultrasound
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Thomas Jefferson University
Neuroblastoma, Sarcoma
Vaccine Therapy and Interleukin-2 in Treating Young Patients With Relapsed or Refractory Ewing's Sarcoma or Neuroblastoma
RATIONALE: Vaccines made from a person's tumor cells and white blood cells may make the body build an effective immune response to kill tumor cells. Interleukin-2 (IL-2) may stimulate the white blood cells to kill tumor cells.
- Trial name
- NCT00101309
- Testing
- aldesleukin, autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Milton S. Hershey Medical Center
Childhood Malignant Fibrous Histiocytoma of Bone, Sarcoma
Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy, such as ifosfamide and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00334854
- Testing
- doxorubicin hydrochloride, ifosfamide, adjuvant therapy
- Where
- 28 sites in Austria, Belgium and 7 more
- Volunteers
- 250 people
- Sponsor
- European Paediatric Soft Tissue Sarcoma Study Group
Solid Tumors, Urothelial Carcinoma
A Study Evaluating MM-310 in Patients With Solid Tumors
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells. Docetaxel is an approved chemotherapeutic drug.This study is a Phase 1 open-label study of MM-310 in patients with solid…
- Conditions
- Solid Tumors, Urothelial Carcinoma, Gastric Carcinoma, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03076372
- Testing
- MM-310
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Merrimack Pharmaceuticals
Breast Cancer, Colorectal Cancer
Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors
RATIONALE: Bortezomib may stop the growth of solid tumors by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Conditions
- Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00620295
- Testing
- bortezomib, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Progression, Survival
PD-L1 Expression in Advanced Osteosarcoma
The expression level of PD-L1 on tumor cells is a pivotal point which might have some influence on prognosis, especially for those who might use PD-1 or PD-L1 antibody for treatment.
- Trial name
- NCT03582527
- Testing
- all study participants
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Peking University People's Hospital
MPNST, NF1
Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas
A multi-institutional open-label phase 1/2 trial of selumetinib in combination with ZEN-3694 and durvalumab in refractory/unresectable sarcomas including MPNST.
- Conditions
- MPNST, NF1, Sarcoma
- Trial name
- NCT05253131
- Testing
- Selumetinib + ZEN-3694 ± Durvalumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Alabama at Birmingham
Synovial Sarcoma, Single or Multiple Lung Metastases
Whole Lung IMRT in Children and Adults With Synovial Sarcoma and Lung Metastases
The purpose of this study is to find out what effects, good and/or bad, radiation has on the lungs has on the patient and on synovial sarcoma which has spread to the lungs.
- Trial name
- NCT02181829
- Testing
- Whole Lung IMRT
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Sarcoma, Environmental Exposure
Etiosarc: Environmental Aetiology of Sarcomas From a Multicenter French Population-based Case-control Study Among Adults
Introduction: Sarcomas are rare tumors of connective tissue. The exact overall incidence of sarcomas is unknown due to diagnostic difficulties and the various histological subtypes (over 80 subtypes).
- Conditions
- Sarcoma, Environmental Exposure, Occupational Exposure, Life Style
- Trial name
- ETIOSARC (NCT03670927)
- Testing
- Environmental, occupational and lifestyle-related exposures
- Where
- 10 sites in France
- Volunteers
- 2,237 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Bladder Cancer, Breast Cancer
Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Colony-stimulating factors such as filgrastim may increase the number of immune cells found in bone marrow or…
- Conditions
- Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer
- Trial name
- NCT00014456
- Testing
- filgrastim, docetaxel, gemcitabine hydrochloride
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult
A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors
This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0111 when administered intratumorally in…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma Adult, Triple Negative Breast Cancer
- Trial name
- NCT06700070
- Testing
- PBA-0111
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Pure Biologics S.A.
Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma
Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
This phase Ib trial studies the side effects of navtemadlin and radiation therapy in treating patients with soft tissue sarcoma.
- Trial name
- NCT03217266
- Testing
- Navtemadlin, Radiation Therapy, Surgical Procedure
- Where
- 53 sites in United States
- Volunteers
- 39 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Kaposi, HIV Infections
SU5416 in Patients With AIDS-Related Kaposi's Sarcoma Who Have Not Responded to Treatment
The purpose of this study is to test the effectiveness of SU5416 in patients with AIDS-related Kaposi's sarcoma (KS).
- Trial name
- NCT00005931
- Testing
- SU5416
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- SUGEN
Osteosarcoma
ABCB1/P-glycoprotein Expression Influence on Non-metastatic Osteosarcoma of the Extremities
Post-authorization, observational, multicenter and prospective study in patients between 2 and 30 years old diagnosed with non-metastatic high-grade osteosarcoma of the extremities.
- Trial name
- NCT04383288
- Where
- 17 sites in Spain
- Volunteers
- 115 people
- Sponsor
- Grupo Espanol de Investigacion en Sarcomas
Soft Tissue Sarcoma
Adriamycin and Ifosfamide Combined With Sintilimab
The aim of this study was to explore the efficacy and safety of adriamycin and ifosfamide combined with sintilimab versus chemotherapy in the treatment of advanced or unresectable soft tissue sarcoma.
- Trial name
- NCT04589754
- Testing
- Sintilimab plus chemotherapy, Adriamycin-based chemotherapy
- Where
- China
- Volunteers
- 176 people
- Sponsor
- Sun Yat-sen University
Soft Tissue Sarcoma
Anrotinib Hydrochloride Combined With Adriamycin for Neoadjuvant Treatment of High-grade Soft Tissue Sarcoma
This is an investigator-initiated, single-arm, single-center, prospective clinical study with an estimated 58 patients enrolled to explore the efficacy and safety of anrotinib hydrochloride in combination with doxorubicin and…
- Trial name
- NCT05747521
- Testing
- Anrotinib hydrochloride combined with adriamycin
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Henan Cancer Hospital
Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm
A Phase 1/2 Study of CBX-12 in Children, Adolescents, or Young Adults With Solid Tumors That Have Come Back After Treatment or Are Difficult to Treat
This phase I/II trial tests the safety, best dose, and effectiveness of CBX-12 in the treatment of pediatric patients (ages 12 months to 30 years) with rhabdomyosarcoma, Ewing sarcoma, or other extracranial solid tumors that have…
- Conditions
- Recurrent Childhood Ewing Sarcoma, Recurrent Childhood Malignant Solid Neoplasm, Recurrent Childhood Rhabdomyosarcoma, Recurrent Ewing Sarcoma
- Trial name
- NCT07830667
- Testing
- Archive Sample Retrieval, Biospecimen Collection, pH Low Insertion Peptide-exatecan Conjugate CBX-12
- Volunteers
- 79 people
- Sponsor
- Children's Oncology Group
Rhabdomyosarcoma
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
- Trial name
- FaR-RMS (NCT04625907)
- Testing
- Irinotecan, Actinomycin D, Doxorubicin
- Where
- 128 sites in Australia, Austria and 18 more
- Volunteers
- 1,672 people
- Sponsor
- University of Birmingham
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.